Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients
Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- RCCI
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a history of exposure to sulfur mustard with a complaint of dyspnea
Exclusion Criteria:
- A contraindication for furosemide use;
- An accompanying disease in which other drugs effective for dyspnea were used
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
effect of furosemid inhalation on dyspnea
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mostafa Ghanei, MD, Research Center of Chemical Injuries, Baqiyatallah Medical Science University, Tehran, Iran
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Bronchial Diseases
- Signs and Symptoms, Respiratory
- Lung Diseases, Obstructive
- Bronchitis
- Respiratory Aspiration
- Bronchiolitis
- Dyspnea
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Potassium Chloride Symporter Inhibitors
- Furosemide
Other Study ID Numbers
Other Study ID Numbers
- 121a25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis
-
NCT07239895RecruitingPediatric Bronchiolitis Obliterans
-
NCT03805477RecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)
-
NCT07234760CompletedBronchiolitis Obliterans Syndrome (BOS)
-
NCT05899894CompletedAcute Viral Bronchiolitis
-
NCT01777347CompletedAcute Viral Bronchiolitis
-
NCT01873144CompletedAcute Viral Bronchiolitis
-
NCT06920199Recruiting
-
NCT01273207CompletedBronchiolitis Obliterans | Graft Versus Host Disease | Graft-Versus-Host Disease | Constructive Bronchiolitis | Bronchiolitis, Exudative | Bronchiolitis, Proliferative
-
NCT07395232RecruitingAtopic Keratoconjunctivitis
-
NCT05799677CompletedReflexology | Bronchiolitis; Chemical
Clinical Trials on furosemide
-
NCT07577596Not yet recruitingAcute Heart Failure | Volume Overload
-
NCT07464249CompletedAcute Decompensated Heart Failure (ADHF)
-
NCT03946891WithdrawnPremature Birth | Premature Infant
-
NCT06229990Recruiting
-
NCT00577135Completed
-
NCT07263035RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IV
-
NCT07167862Not yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe or Mild
-
NCT02527798CompletedBronchopulmonary Dysplasia